Topic immunotherapy with 5% imiquimod in complex clinical scenarios of basal cell skin cancer
Summary. The aim of the study was to evaluate the efficacy and tolerability of topical immunotherapy with 5% imiquimod in patients with basal cell carcinoma (BCC), including H-zone tumors and multiple lesions in Gorlin syndrome, taking into account the European Association of Dermato-Oncology (EADO) classification (2021). Three clinical cases are presented with morphological verification of the diagnosis, EADO staging and multidisciplinary definition of treatment tactics; imiquimod was used according to standard regimens with dynamic clinical and dermatoscopic control. In all cases, clinical remission with good cosmetic results was achieved; local inflammatory reactions correlated with therapeutic response and were controlled. Therefore, imiquimod can be considered as an effective non-invasive alternative to surgery in carefully selected patients, subject to regular monitoring.
Leave a comment